This trial will study how well a drug called copanlisib works in patients with relapsed or refractory B-ALL.
- Acute Lymphoblastic Leukemia
1 Primary · 2 Secondary · Reporting Duration: 1 year
Side Effects for
Awards & Highlights
1 Treatment Group
1 of 1
10 Total Participants · 1 Treatment Group
Primary Treatment: Copanlisib · No Placebo Group · Phase < 1
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this experiment pioneering a new approach to treatment?
"Since 2012, Bayer has sponsored research into copanlisib. After the first study in that year with 227 participants, it was given Phase 2 drug approval. Nowadays, there are 32 active trials of this medication across 983 cities and 46 countries." - Anonymous Online Contributor
Are there any prior experimental findings concerning Copanlisib?
"Currently, there are 32 studies that focus on Copanlisib with two of them in their terminal stage. Most trials for the drug take place in Houston, Texas yet an additional 2118 sites worldwide host experiments regarding its efficacy." - Anonymous Online Contributor
Is this experiment presently open to participating subjects?
"Affirmative. According to the information on clinicaltrials.gov, recruitment for this research project is still in progress after being initially posted on June 21st 2021 and last updated on June 28th 2022. The study requires 10 volunteers from a single site." - Anonymous Online Contributor
What population is participating in the experiment?
"Affirmative. According to the information on clinicaltrials.gov, this research endeavour is currently recruiting participants after being first posted on June 21st 2021 and last updated on June 28th 2022. This trial requires a total of 10 patients from 1 medical centre for enrolment." - Anonymous Online Contributor